National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$44.00
add to cart

Rights & Permissions

topleft topright

Rare Diseases and Orphan Products: Accelerating Research and Development (2011)
Board on Health Sciences Policy (HSP)

Citation Manager

. "Appendix C: Medicare Part D Coverage and Reimbursement of Orphan Drugs." Rare Diseases and Orphan Products: Accelerating Research and Development. Washington, DC: The National Academies Press, 2011.

Please select a format:

BibTeX EndNote RefMan


Page
328
bottomleft bottomright

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.


Rare Diseases and Orphan Products: Accelerating Research and Development

Exclusivity Start Date

Generic Name

Trade Name

Indication for Original Approvala

8/28/01

Topiramated

Topamax

As adjunctive therapy in patients 2 years and older with seizures associated with Lennox-Gastaut syndrome

11/20/01

Bosentan

Tracleer

Treatment of pulmonary arterial hypertension

1/18/02

Nitisinone

Orfadin

Adjunctive therapy to dietary restriction of tyrosine and phenylalanine in treatment of hereditary tyrosinemia type 1

7/17/02

Oxybate

Xyrem

Treatment of cataplexy associated with narcolepsy

10/8/02

Buprenorphine in combination with naloxone

Suboxone

Treatment of opioid dependence in patients 16 years of age or older

10/8/02

Buprenorphine hydrochlorided

Subutex

Treatment of opioid dependence in patients 16 years of age or older

11/22/02

Nitazoxanide

Alinia

Treatment of diarrhea caused by Cryptosporidium parvum and Giardia lamblia

3/25/03

Pegvisomantc

Somavert

Treatment of acromegaly in patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapies, or for whom these therapies are not appropriate

7/31/03

Miglustatd

Zavesca

Treatment of mild to moderate Type I Gaucher disease in adults for whom enzyme replacement therapy is not a therapeutic option

12/1/03

Somatropin (r-DNA)c,e

Zorbtive

Treatment of short bowel syndrome in patients receiving specialized nutritional support

3/8/04

Cinacalcetd

Sensipar

Treatment of hypercalcemia in patients with parathyroid carcinoma

4/20/04

Apomorphine HClc

Apokyn

For the acute, intermittent treatment of hypomobility, “off” episodes, associated with advanced Parkinson’s disease

5/17/04

Tinidazole

Tindamax

(1) Treatment of giardiasis caused by G. duodenalis (also termed G. lamblia). (2) Treatment of intestinal amebiasis and amebic liver abcess caused by E. histolytica.

Page
328